Piper Sandler upgraded ImmunityBio (IBRX) to Overweight from Neutral with a price target of $5, up from $4.25.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- Short Report: Bears not fearing rebound in Rocket, Avis Budget shares
- ImmunityBio Sees Revenue Surge Amid Strong Sales Momentum
- ImmunityBio’s Promising Growth and Strategic Expansion Justify Buy Rating Despite Regulatory Setback
- ImmunityBio reports Q1 EPS (15c), consensus (14c)
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue